Email Alert | RSS    帮助

中国防痨杂志 ›› 2019, Vol. 41 ›› Issue (2): 233-235.doi: 10.3969/j.issn.1000-6621.2019.02.020

• 综述 • 上一篇    下一篇

间充质干细胞在结核病治疗中的应用与问题

吴蓓蓓,黄薇,王志敏()   

  1. 201203 国家人类基因组南方研究中心上海市疾病与健康基因组学重点实验室 上海产业技术研究院
  • 收稿日期:2018-09-14 出版日期:2019-02-10 发布日期:2019-02-01
  • 通信作者: 王志敏 E-mail:wangzhm@chgc.sh.cn
  • 基金资助:
    国家自然科学基金重点项目(51833006);上海科学技术委员会重大专项(15411953400);上海市人才发展资金(2017120);上海科学院专项基金(SKY2018002)

The applications and problems of mesenchymal stem cells for the treatment of tuberculosis

Bei-bei WU,Wei HUANG,Zhi-min WANG()   

  1. Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Centre and Shanghai Industrial Technology Institute (SITI), Shanghai 201203, China
  • Received:2018-09-14 Online:2019-02-10 Published:2019-02-01
  • Contact: Zhi-min WANG E-mail:wangzhm@chgc.sh.cn

摘要:

结核病由于其高死亡率和高发病率,是世界最严重的传染病之一。尽管人体具备强大的免疫系统,但结核分枝杆菌还是逃过了宿主的免疫,建立了一种持续感染的状态。由于抗结核药物研制发展缓慢,而结核分枝杆菌又在不断发生变化,结核病的防治一直都是人类面临的重大难题。近些年,由于间充质干细胞的免疫调节等特性被逐渐发现和证实,人们发现间充质干细胞有望给临床上治疗结核病带来新的希望。作者就间充质干细胞参与结核病治疗中的应用与问题进行了综述。

关键词: 结核, 间质干细胞, 免疫调节, 治疗应用

Abstract:

Tuberculosis is one of the most serious infectious diseases in the world because of its high mortality and morbidity. Despite the robust immune response of human, Mycobacterium tuberculosis (MTB) evades host immunity and sets up a persistent infection. With the advances of medicine there have been some drugs to treat tuberculosis, but due to slow development of anti-tuberculosis drugs and the constant variation of MTB, prevention and management of tuberculosis is still a global health problem threatening thousands of lives. Recently, with the discovery and confirmation of its immunomodulatory property, the mesenchymal stem cells could give us new expectations for clinical management of tuberculosis. The authors summarize the applications and problems about mesenchymal stem cells for tuberculosis.

Key words: Tuberculosis, Mesenchymal stem cells, Immunomodulation, Therapeutic uses